.png){kind=icon}
.png){kind=icon}
Return
Collagenous Gastritis: Characteristics and Response to Topical Budesonide
.png){kind=icon}
PRE
AI
DOI：10.1016/j.cgh.2021.11.033.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
BACKGROUND AND AIMS: Collagenous gastritis (CG) is a rare disorder characterized by subepithelial collagen deposition in the stomach. Standard medications have been only moderately successful in treating CG. We report results of a large, retrospective, open-label noncontrolled study of topical budesonide for CG, with an aim of establishing an alternative therapy for the disease. METHODS: We identified patients treated for CG at Mayo Clinic (2000-2017) with topically targeted budesonide (TTB) in 2 formulations: open-capsule budesonide or compounded immediaterelease budesonide capsule. Demographic, clinical, biochemical, and histologic variables were assessed for all patients before and after treatment. RESULTS: We identified 64 patients with CG (50 adults, 14 children). Most were female (68%), mean age was 41 +/- 22.8 years, and body mass index was 23.1 +/- 5.9 kg/m(2). In most pediatric patients, CG presented with abdominal pain and anemia; in adults, CG presented more often with weight loss (P <.001). Collagenous sprue or colitis were more common in patients >50 years of age (83%) vs those 19-50 years of age (27%) or <19 years of age (50%) (P <.001). Of the patients treated with TTB, 89% had a clinical response to TTB (42% complete, 46% partial), and 88% had a histologic response (53% complete, 33% partial). CONCLUSIONS: Adults and children with CG have a wide variety of symptoms, and notably, TTB therapy produced clinical and histologic improvement after other therapy had failed.
Keywords:
Budesonide
Corticosteroids
Collagenous Gastritis
Journal
IF:
12
Papers:
9.6K
Citations:
3.1W